Abstract
Background: Cutaneous melanoma is the 15th most common cancer worldwide. Ireland has the 4th highest incidence rate in Europe in women and the 8th highest incidence rate in men. Sentinel lymph node biopsy (SLNB) is an essential part of the melanoma staging process for intermediate and thick melanomas, however, the exact survival benefit is unclear. As part of this systematic review we wish to assess the literature regarding SLNB in cutaneous melanoma patients, specifically relating to survival benefit.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
